Gilead Sciences reported $13.04B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Moderna USD 1.18B 223M Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 598M Sep/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026